Answers are grounded in this paper and cite their sources.
Case report of metaplastic carcinoma in a transgender female shows continued mass growth despite treatment, highlighting the need for awareness.
Introduction/Objective Metaplastic carcinoma is an uncommon type of breast cancer, accounting for 0.2–1% of invasive breast malignancies. It is even rarer in transgender females. To our knowledge, this is the first reported case of metaplastic breast carcinoma in a transgender female. Methods/Case Report A 40-year-old transgender female on chronic estrogen, progesterone, and spironolactone therapy presented with a two-month history of a palpable left breast mass. Imaging revealed an 8 cm BI-RADS 4 lesion in the upper outer quadrant. Core needle biopsy showed a high-grade malignant neoplasm with a predominant spindle cell component and scattered vague glandular structures. Brisk mitotic activity was noted. Immunohistochemical stains revealed focal positivity for PanCK, CK5/6, and p63; diffuse strong vimentin positivity; ER-negative, PgR weakly positive (1%), HER2-negative, and Ki-67 at 90%. A final diagnosis of poorly differentiated malignant spindle cell tumor, favoring metaplastic carcinoma, was made. Despite the initiation of chemotherapy, the mass continued to grow in size. Additional stains showed rare EMA positivity, focal CD99 positivity, non-specific BCL-2 staining, and negativity for SMA, Desmin, and CD34. Results NA Conclusion Despite the rarity of metaplastic carcinoma diagnosis, it is necessary to be alert to this pathology in various cases to ensure timely and accurate diagnosis and treatment of the patient.
No takes yet. Share an insight, caveat, or question.
Movchan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: